Pasireotide
Specialist research
It has phase II/III research in Cushing’s disease and acromegaly and distinct investigations in neuroendocrine tumors and perioperative pancreatic settings.
An authorisation applies to at least one defined finished product in a stated jurisdiction; it does not apply automatically to this catalogue material.
What is Pasireotide?
Pasireotide is a synthetic somatostatin analogue with broad somatostatin receptor affinity used in neuroendocrine and endocrine research; the catalogue entry denotes research grade pasireotide material supplied for laboratory study.
Which research context has Pasireotide been associated with?
Pasireotide is associated with translational and clinical endocrinology research as a synthetic somatostatin analogue, including phase II/III studies in Cushing’s disease and acromegaly, investigations in neuroendocrine tumours, and perioperative endocrine modulation studies in pancreatic contexts.
What documentation is available for Pasireotide?
Pasireotide: Batch documents are not yet linked on this site. Documentation required for this synthetic somatostatin analogue includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and purity limits; peptide content, counterion and residual solvent/water data; and potency/assay method used for specification. No batch documentation is shown as available until the record for that specific item is linked and reviewed.
What determines the storage conditions for Pasireotide?
Pasireotide: Storage depends on the documented supplied presentation; as a synthetic somatostatin analogue confirm dry/lyophilised or solution form, counterion and concentration, solvent or buffer selection, pH sensitivity, container closure compatibility and freeze/thaw stability to assess chemical integrity and aggregation risk. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.